Rôle de la parathormone dans l’ostéoporose

Ultrasound bone mass in schizophrenic patients on antipsychotic therapy

OBJECTIVE

To determine bone mass using quantitative phalangeal bone ultrasound in institutionalized schizophrenic patients under chronic treatment with antipsychotic drugs.

METHODS

A total of 73 patients with schizophrenia (25 women, mean age 59.84 +/- 17.01 years; 48 men, mean age 61.89 +/- 12.95 years) and 73 healthy subjects (25 women, mean age 60.37 +/- 17.16 years; 48 men, mean age 61.24 +/- 13.09 years) participated in the study. Bone status was assessed using an ultrasound device that measures the amplitude-dependent speed of sound (Ad-SoS) in metres per second. Measurements were made on the phalanges (II-V) of the non-dominant hand, and the mean value was computed.

RESULTS

The schizophrenic women had higher levels of prolactin (PRL), parathyroid hormone (PTH), alkaline phosphatase (AlPh), and tartrate-resistant acid phosphatase (TRAP) (all p < 0.0001), and lower 25-hydroxyvitamin D(25(OH)D3) levels (p < 0.0001) and Ad-SoS values (p < 0.05) than controls. Ad-SoS was higher in schizophrenic men (p < 0.05).

CONCLUSIONS

Schizophrenic women in treatment with antipsychotic drugs had a loss of phalangeal bone mass that was associated with the levels of vitamin D or PTH, and increased bone turnover.

Diagnostic de l’ostéoporose: quels examens biologiques faut-il faire ?

Malignant or metabolic causes of low bone mineral density must be sought after either a fragility fracture or the discovery of low bone density measurements. Laboratory tests for calcium and phosphate metabolism are normal in osteoporosis. Vitamin D deficiency is frequent and requires supplementation. Markers of bone remodeling can be useful in cases where the treatment decision is difficult.